NICE recommends treatment for early breast cancer

NICE recommends Pertuzumab for treatment of early breast cancer


The United Kingdom’s National Institute for Health and Care Excellence (NICE) today released a final appraisal of pertuzumab (Perjeta) together with intravenous trastuzumab and chemotherapy for the treatment of HER2-positive early breast cancer, and recommended pertuzumab for use in patients if they have lymph node–positive disease and if drug maker Roche adheres to its promised discount for the drug.

NICE’s final appraisal indicates that Roche has offered the National Health Service (NHS) a discount on the drug, which carries a UK list price of £2395 (approximately $3068) per 420-mg vial. That discount, taken together with the cost savings made possible by biosimilar trastuzumab agents that have recently entered the UK market, brings the cost-effectiveness estimate for the therapy per quality-adjusted life-year (QALY) gained to “comfortably below £20,000,” or below approximately $25,627, which is NICE’s typical cost-effectiveness threshold.

Read the full article by The Center for Biosimilars Staff here

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.